Moneycontrol PRO
Loans
Loans
HomeNewsIpcalaboratories

Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

Jump to
  • Like Mangalam Cement, Mahindra CIE: Sudip Bandopadhyay

    Sudip Bandopadhyay of Destimoney Securities is of the view that one may prefer midcap stocks like Mangalam Cement, Mahindra CIE and Ramkrishna Forgings.

  • Your stocks: What to buy/sell/hold in volatile market

    Watch the interview of Sameet Chavan of Angel Broking who shared his readings and outlook on specific stocks and sector & Kalpesh Ashar of Full Circle Financial Planners & Advisors answered few personal finance queries.

  • Enter Sun Pharma, Dr Reddy's on dips: Sameet Chavan

    According to Sameet Chavan of Angel Broking, one may buy Sun Pharmaceutical Industries and Dr Reddy's Laboratories on dips.

  • Ipca Labs attractive buy, says Rahul Mohindar

    Rahul Mohindar of viratechindia.com is of the view that Ipca Labs is an attractive buy.

  • Prefer midcap stocks: Pankaj Murarka

    Pankaj Murarka of Axis Asset Management is of the view that one may prefer midcap stocks.

  • Prefer banking, auto space: Vikas Khemani

    Vikas Khemani ,CEO at Edelweiss Securities is of the view that one may prefer banking and auto space and feels that midcaps are opportunities on correction.

  • Prefer midcap pharma stocks on correction: Kunj Bansal

    Kunj Bansal of Centrum Wealth Management is of the view that one may prefer midcap pharma stocks on correction.

  • Prefer midcap pharma companies: Taher Badshah

    Taher Badshah of Motilal Oswal AMC is of the view that one will keep getting opportunities on mid-size companies.

  • Prefer midcap pharma companies: Taher Badshah

    Taher Badshah of Motilal Oswal AMC is of the view that one may prefer midcap pharma companies.

  • Positive on Lupin on strong pipeline for US mkt: IIFL

    Pharma Analyst, Abhishek Sharma of IIFL spoke with Ekta Batra & Anuj Singhal of CNBC-TV18. He shared his reading and outlook on the pharmaceutical space.

  • Hold Ipca Laboratories, says Mayuresh Joshi

    Mayuresh Joshi of Angel Broking is of the view that one may hold Ipca Laboratories.

  • Hold Ipca Laboratories: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com recommends holding Ipca Laboratories.

  • Hold IPCA Laboratories for long term: Taher Badshah

    Taher Badshah of Motilal Oswal AMC is of the view that one may hold IPCA Laboratories with a long term view.

  • Here are top 10 stocks to keep an eye on March 25

    Here are top 10 stocks to keep an eye on March 25 - Tata Motor DVR, Tata Motors, Bharti Airtel, Idea Cellular, GMR Infra, Ipca Labs, IOC, BPCL, Oil India and NTPC.

  • Sun Pharma, Lupin top picks: Devang Mehta

    Devang Mehta of Anand Rathi Financial Services is of the view that Sun Pharma and Lupin still remains the top picks.

  • Prefer pharma stocks: Sudarshan Sukhani

    Sudarshan Sukhani of s2analytics.com is of the view that one may prefer pharma stocks.

  • Prefer Dr Reddy's, Lupin, Cipla, Ipca Labs: Anmol Ganjoo

    Anmol Ganjoo of JM Financial Institutional Securities is of the view that one may prefer Dr Reddy's Laboratories, Lupin, Cipla, Ipca Labs and Torrent Pharma.

  • Prefer MphasiS, KPIT, Exide: Dilip Bhat

    Dilip Bhat of Prabhudas Lilladher is of the view that one may prefer MphasiS, KPIT Tech and Exide Industries.

  • Go long in IPCA Laboratories: Amit Harchekar

    Amit Harchekar of A PLUS Analytics is of the view that one can go long in IPCA Laboratories with a target of Rs 785-800.

  • Prefer Wockhardt: Sharmila Joshi

    Sharmila Joshi of sharmilajoshi.com is of the view that one may prefer Wockhardt.

  • Here are top 10 stocks to keep an eye on February 9

    Here are top 10 stocks to keep an eye on February 9 - Tata Power, Reliance Infra, DLF, Tata Steel, Jet Airways, Jammu and Kashmir Bank (J&K) Bank, Marico Kaya, Apollo Tyres, IPCA Labs, Balmer Lawrie, TV Today, Technocraft, Vascon Engineers, Pricol AND VA Tech Wabag.

  • Here are top 10 stocks to keep an eye on January 23

    Here are top 10 stocks to keep an eye on January 23 - ICICI Bank, Axis Bank, Cairn India, Prestige Estates, Biocon, Ipca Labs, Polaris, Phillips Carbon, Mahindra Holidays and HCL Infosystems.

  • Here are top 10 stocks to focus on January 13

    Here are top 10 stocks to focus on January 13 - Cairn India, Jet Airways, Apollo Tyres, Ceat, Crompton Greaves, Bank Nifty, Hindalco, CMC, Clariant Chemicals and Spicejet. We are also watching Dr Reddy's, Sun Pharma, Ipca Labs, Lupin, Cipla, ACC and Ultratech.

  • Here are top 10 stocks to focus on December 23

    Here are top 10 stocks to focus on December 23 - HDFC, SBI, Bank Nifty, Ipca Labs, HCL Tech, Intellect Design Arena, Max India, Rel Cap, NTPC and Gujarat Pipavav.

  • Ipca Labs preferred bet: Mayuresh Joshi

    Mayuresh Joshi, VP- Institution at Angel Broking is of the view that Ipca Labs is the preferred bet from the midcap pharma space.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347